Evaluation of Biomarkers of Atopic Dermatitis in Pediatric Patients

Updated 06/21/2024

Status Active, not recruiting

Clinical Trial Summary

Primary Objective: To explore associations between biomarkers of atopic dermatitis (AD) and: - Disease state and time course of AD, - Disease state and evolution of selected atopic comorbid conditions, - Effectiveness of specific AD treatments.

Clinical Trial Description

The estimated enrollment duration is approximately 2 years, while duration of observation is approximately 5 years. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03849716
Study type	Observational [Patient Registry]
Source	Sanofi
Contact
Status	Active, not recruiting
Phase
Start date	April 5, 2019
Completion date	September 30, 2026

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT06015308` - A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo	Phase 2
	Completed	`NCT04135560` - A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants	Phase 1
	Recruiting	`NCT06130566` - A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis	Phase 3
	Recruiting	`NCT06192563` - A Study to Observe How Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16) Respond to Dupilumab Treatment
	Completed	`NCT05624112` - Dupilumab Skin BArrier Function and LIpidomics STudy in Atopic Dermatitis in China	Phase 4
	Recruiting	`NCT06407934` - A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Monotherapy Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis	Phase 3
	Active, not recruiting	`NCT03992417` - Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)
	Recruiting	`NCT06224348` - A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids	Phase 3
	Completed	`NCT05214326` - A Study to Assess the Disease Control of Moderate to Severe Atopic Dermatitis in Male and Female Participants of Atleast 12 Years Old Receiving Dupilumab Injections in Gulf Countries
	Recruiting	`NCT06241118` - A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor	Phase 3
	Recruiting	`NCT05983068` - A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis	Phase 4
	Completed	`NCT04718870` - Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis	Phase 4
	Completed	`NCT05235724` - A Study to Assess the Reliability/Feasibility of Using Emerald Touchless Sensor for Scratching and Sleep Quantification in a Subset of Participants From PEDISTAD Study (OBS15333; NCT03687359)
	Recruiting	`NCT06181435` - A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)	Phase 3
	Recruiting	`NCT05492578` - Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials	Phase 2
	Recruiting	`NCT03687359` - Observational Evaluation of Atopic Dermatitis in Pediatric Patients
	Recruiting	`NCT05769777` - Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis	Phase 2
	Completed	`NCT04823130` - Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis	Phase 4